Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raisingA systematic review and meta-analysis of relevant preclinical studies and clinical trials
- 1 September 2015
- journal article
- review article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 763, 48-63
Abstract
No abstract availableKeywords
This publication has 105 references indexed in Scilit:
- Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation studyThe Lancet, 2012
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Fenofibrate Increases Very Low Density Lipoprotein Triglyceride Production Despite Reducing Plasma Triglyceride Levels in APOE*3-Leiden.CETP MiceJournal of Biological Chemistry, 2010
- Fibrates, Glitazones, and Peroxisome Proliferator–Activated ReceptorsArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Effects of Combination Lipid Therapy in Type 2 Diabetes MellitusNew England Journal of Medicine, 2010
- Increased HDL Cholesterol and ApoA-I in Humans and Mice Treated With a Novel SR-BI InhibitorArteriosclerosis, Thrombosis, and Vascular Biology, 2009
- Major Lipids, Apolipoproteins, and Risk of Vascular DiseaseJAMA, 2009
- Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitorsEuropean Heart Journal, 2009
- The dual PPARα/γ agonist tesaglitazar blocks progression of pre‐existing atherosclerosis in APOE*3Leiden.CETP transgenic miceBritish Journal of Pharmacology, 2009
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986